CME in the 13F filings
Cme Group Inc · CUSIP 12572Q105
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 14 Feb 2025
- latest of these filings; the earliest 31 Jan 2025
- Managers listing it
- 35
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 30 listed it in both
- Shares listed
- 47,759,827
- combined, among listed positions
- Reported value
- $11.1bn
- combined, at the quarter end
Among the 94 comparable managers: 16 buyers (opened or added shares) and 15 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing CME in Q4 2024
35 of 35 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 8,280,785 shares now+3,921,278
- Egerton Capital UK LLPnew position · 964,421 shares now+964,421
- Arrowstreet Capital LPexisting position · 3,416,361 shares now+819,158
- Janus Henderson Group Ltdexisting position · 3,135,753 shares now+621,713
- AQR Capital Management LLCexisting position · 2,523,694 shares now+598,027
Reductions
- Balyasny Asset Management LLCexisting position · 144,017 shares now-1,141,943
- Capital World Investorsexisting position · 11,212,713 shares now-918,317
- Millennium Management LLCexisting position · 905,366 shares now-886,945
- D. E. Shaw & Co.existing position · 344,721 shares now-654,501
- Voloridge Investment Management LLCexisting position · 473,248 shares now-505,574
New positions and exits
New (3)
- Egerton Capital UK LLP$224m
- Woodline Partners LP$5.0m
- Markel Group Inc$697k
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 23 | $5.0bn | n.a. | n.a. |
| Q3 2013 | 21 | $5.0bn | n.a. | n.a. |
| Q4 2013 | 19 | $4.5bn | n.a. | n.a. |
| Q1 2014 | 18 | $4.2bn | n.a. | n.a. |
| Q2 2014 | 19 | $4.2bn | n.a. | n.a. |
| Q3 2014 | 18 | $5.1bn | n.a. | n.a. |
| Q4 2014 | 19 | $5.6bn | n.a. | n.a. |
| Q1 2015 | 22 | $5.8bn | n.a. | n.a. |
| Q2 2015 | 22 | $5.5bn | n.a. | n.a. |
| Q3 2015 | 25 | $5.2bn | n.a. | n.a. |
| Q4 2015 | 24 | $4.9bn | n.a. | n.a. |
| Q1 2016 | 26 | $5.4bn | n.a. | n.a. |
| Q2 2016 | 29 | $6.0bn | n.a. | n.a. |
| Q3 2016 | 27 | $5.8bn | n.a. | n.a. |
| Q4 2016 | 30 | $6.3bn | n.a. | n.a. |
| Q1 2017 | 30 | $6.4bn | n.a. | n.a. |
| Q2 2017 | 35 | $7.0bn | n.a. | n.a. |
| Q3 2017 | 31 | $7.7bn | n.a. | n.a. |
| Q4 2017 | 30 | $7.8bn | n.a. | n.a. |
| Q1 2018 | 33 | $8.8bn | n.a. | n.a. |
| Q2 2018 | 32 | $9.9bn | n.a. | n.a. |
| Q3 2018 | 30 | $10.5bn | n.a. | n.a. |
| Q4 2018 | 27 | $12.4bn | n.a. | n.a. |
| Q1 2019 | 31 | $12.0bn | n.a. | n.a. |
| Q2 2019 | 28 | $14.6bn | n.a. | n.a. |
| Q3 2019 | 29 | $16.0bn | n.a. | n.a. |
| Q4 2019 | 28 | $15.3bn | n.a. | n.a. |
| Q1 2020 | 32 | $13.4bn | n.a. | n.a. |
| Q2 2020 | 32 | $12.2bn | n.a. | n.a. |
| Q3 2020 | 32 | $11.8bn | n.a. | n.a. |
| Q4 2020 | 26 | $11.4bn | n.a. | n.a. |
| Q1 2021 | 26 | $12.3bn | n.a. | n.a. |
| Q2 2021 | 26 | $12.8bn | n.a. | n.a. |
| Q3 2021 | 30 | $11.6bn | n.a. | n.a. |
| Q4 2021 | 26 | $14.6bn | n.a. | n.a. |
| Q1 2022 | 32 | $15.8bn | n.a. | n.a. |
| Q2 2022 | 37 | $13.4bn | n.a. | n.a. |
| Q3 2022 | 38 | $10.9bn | n.a. | n.a. |
| Q4 2022 | 36 | $9.1bn | n.a. | n.a. |
| Q1 2023 | 32 | $9.6bn | n.a. | n.a. |
| Q2 2023 | 34 | $9.5bn | n.a. | n.a. |
| Q3 2023 | 33 | $9.8bn | n.a. | n.a. |
| Q4 2023 | 32 | $10.2bn | 18 | 14 |
| Q1 2024 | 30 | $8.9bn | 13 | 16 |
| Q2 2024 | 33 | $8.3bn | 20 | 11 |
| Q3 2024 | 35 | $10.0bn | 22 | 12 |
| Q4 2024 | 35 | $11.1bn | 16 | 15 |
| Q1 2025 | 35 | $12.1bn | 21 | 13 |
| Q2 2025 | 37 | $12.7bn | 18 | 17 |
| Q3 2025 | 33 | $11.9bn | 14 | 17 |
| Q4 2025 | 31 | $11.1bn | 20 | 26 |
| Q1 2026 | 33 | $11.4bn | 15 | 26 |
| Q2 2026 | 37 | $9.3bn | 31 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CME and V →CME and AXP →CME and BAC →Choose a stock to compare with CME →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CME, latest filings →Back to the 13F Explorer →